James Sietstra is an accomplished investor and entrepreneur with a robust background in founding and leading innovative companies. As the founder of Seven Bridges Genomics from 2012 to 2018, Sietstra played a pivotal role in advancing genomic technologies. Currently, Sietstra spearheads Nephronomics and mechanica, both established in 2023, and previously founded Totient, which was part of Absci from 2018 to 2022. Sietstra's educational credentials include a degree from Harvard University, attended from 2004 to 2008, and ongoing studies at Lincoln High School.
This person is not in the org chart
This person is not in any teams
This person is not in any offices